Arvinas, Inc.
ARVN
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastaticā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$10.57
Price+4.45%
$0.45
1Y
Price
Market Cap
$767.856m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-319.2%
EBITDA Margin-273.2%
Net Profit Margin-431.2%
Free Cash Flow MarginRevenue
$372.800m
+41.5%
1y CAGR+78.9%
3y CAGR+95.5%
5y CAGREarnings
-$72.600m
+63.5%
1y CAGR+26.4%
3y CAGR+7.9%
5y CAGREPS
-$1.01
+63.5%
1y CAGR+32.3%
3y CAGR+14.5%
5y CAGRBook Value
$609.300m
$909.300m
Assets$300m
Liabilities$9.900m
DebtDebt to Assets
1.1%
-0.1x
Debt to EBITDAFree Cash Flow
-$399m
-52.8%
1y CAGR-17.5%
3y CAGR-50.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company